CPF Recognized for Advancing Research and Patient Advocacy Efforts
SAN DIEGO, May 18 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) today announced awards received at the American Thoracic Society's (ATS) International conference in San Diego, Calif. being held this week. The ATS meeting brings together the world's leading pulmonary, critical care and sleep physicians. The CPF received an award for a partner grant program with ATS that, to date, has funded $400,000 in new pulmonary fibrosis research funding. The organization also received a first-time award for its participation in the ATS Public Advisory Roundtable (PAR). The CPF is exhibiting in booth #2921 on "PAR Row" at the International meeting.
The CPF has partnered with the ATS since 2006 to provide peer-reviewed grants for innovative research in PF. To date, the CPF/ATS partner grant program has awarded grants to PF researchers at
"We are pleased to receive some very prestigious awards from ATS, and we're proud to continue this exciting partnership with ATS," said Mishka Michon, CEO of the CPF.
The CPF received the ATS Foundation's inaugural "Breathing for Life Award" for its participation in the ATS PAR, the patient voice of the ATS. The ATS PAR has created unparalleled synergy with ATS members by involving patients in providing support, shaping public policy and stimulating new research.
Due to the CPF's involvement with ATS and combined efforts to further educate doctors and researchers on PF, the disease is gaining more attention and PF is the subject of an increasing number of high profile sessions at the international conference. Sessions on PF at this year's meeting have included topics ranging from basic research areas in lung stem cells as well as clinical and translational research from bench to bedside.
The CPF also awarded an ATS travel grant, provided to fund a PF researcher's conference travel, to James P. Bridges, Ph.D. from Cincinnati Children's Hospital and Medical Center.
About Pulmonary Fibrosis (PF)
Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring -- known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis. Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).
About the CPF
The CPF is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure PF; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of PF issues; and works to improve awareness of PF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 19,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with PF. For more information please visit www.coalitionforpf.org or call (888) 222-8541.
|SOURCE Coalition for Pulmonary Fibrosis|
Copyright©2009 PR Newswire.
All rights reserved